36 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
of significant need for innovative therapies that can demonstrate meaningful benefits beyond hemoglobin increase Disease Overview Market Opportunity No novel
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
companies and have helped to maximize the positive impact of innovative products for patient communities. I am thrilled she is joining the Agios team
8-K
EX-99.1
6rrfwi3ua1sktfz
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
8-K
EX-99.1
zctwygo
12 Jul 22
Agios Appoints Brian Goff as Chief Executive Officer
4:14pm
8-K
EX-99.1
f20hpbhk
5 May 22
Agios Reports Business Highlights and First Quarter 2022 Financial Results
7:21am
8-K
EX-99.1
m002xa4
11 Jun 21
Other Events
7:24am
DEFA14A
4z99x
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
zpuxzpg6
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
s6b34w
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
DEFA14A
EX-99.1
m1vcb ssh067o
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
b684466 mp
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
dhgn2pq e4is89h
12 Jun 20
Entry into a Material Definitive Agreement
7:04am